Tanaproget
- none
- Investigational
- 5-(4,4-Dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1-methyl-1H-pyrrole-2-carbonitrile
- 304853-42-7
- 4369524
- DB04787
- 3572060
- W9F9H8GXWR
- DTXSID00184556
- Interactive image
- CC1(C2=C(C=CC(=C2)C3=CC=C(N3C)C#N)NC(=S)O1)C
- InChI=1S/C16H15N3OS/c1-16(2)12-8-10(4-6-13(12)18-15(21)20-16)14-7-5-11(9-17)19(14)3/h4-8H,1-3H3,(H,18,21)
- Key:PYVFWTPEBMRKSR-UHFFFAOYSA-N
Tanaproget (INN; developmental code names NSP-989, WAY-166989) is an investigational nonsteroidal progestin.[1] It is a high affinity, high efficacy, and very selective agonist of the progesterone receptor (PR).[1] Due to its much more selective binding profile relative to most conventional, steroidal progestins, tanaproget may prove to produce fewer side effects in comparison.[1] As of December 2010,[2] it is in phase II clinical trials in the process of being developed for clinical use as a contraceptive by Ligand Pharmaceuticals.[3][4]
An analog of tanaproget, 4-fluoropropyltanaproget (18F), has been developed as a radiotracer for imaging of the PR in positron emission tomography.[5]
See also
References
- ^ a b c Zhang Z, Olland AM, Zhu Y, et al. (August 2005). "Molecular and pharmacological properties of a potent and selective novel nonsteroidal progesterone receptor agonist tanaproget". J. Biol. Chem. 280 (31): 28468–75. doi:10.1074/jbc.M504144200. PMID 15937332.
- ^ Tanaproget
- ^ Bapst JL, Ermer JC, Ferron GM, Foss D, Orczyk GP (November 2006). "Pharmacokinetics and safety of tanaproget, a nonsteroidal progesterone receptor agonist, in healthy women". Contraception. 74 (5): 414–8. doi:10.1016/j.contraception.2006.06.004. PMID 17046384.
- ^ Bayés M, Rabasseda X, Prous JR (September 2005). "Gateways to clinical trials". Methods Find Exp Clin Pharmacol. 27 (7): 505–22. PMID 16258596.
- ^ Lee JH, Zhou HB, Dence CS, Carlson KE, Welch MJ, Katzenellenbogen JA (June 2010). "Development of [F-18]fluorine-substituted Tanaproget as a progesterone receptor imaging agent for positron emission tomography". Bioconjug. Chem. 21 (6): 1096–104. doi:10.1021/bc1001054. PMID 20496889.
- v
- t
- e
(and progestins)
SPRMsTooltip Selective progesterone receptor modulators | |
---|---|
PRTooltip Progesterone receptor antagonists |
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
- See also
- Progesterone receptor modulators
- Androgens and antiandrogens
- Estrogens and antiestrogens
- List of progestogens
This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e